The therapy has exceeded revenue expectations, with Q3 2024 sales surpassing consensus estimates ... catalysts on the horizon. InvestingPro analysis indicates significant growth potential ...

The therapy has exceeded revenue expectations, with Q3 2024 sales surpassing consensus estimates ... Sarepta’s future growth prospects appear promising, with several potential catalysts on the horizon ...

According to InvestingPro analysis, the stock is currently trading near its Fair Value, with analysts setting price targets ranging from $83 to $169. Ayvakit has been the primary growth driver for ...

This comprehensive analysis examines Salesforce’s current position ... The company offers a suite of cloud applications for sales, service, marketing, and commerce, enabling digital transformation and ...